GTHX

G1 Therapeutics

Last Updated:

Q1'20

Price

quotes and stock data delayed 15 minutes

Cash

$238.3M

Burn Rate (Qtr)

$11.7M

Company Profile

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Trilaciclib (G1T28)

Small Cell Lung Cancer (SCLC)

PDUFA

February 15, 2021

Trilaciclib

Metastatic Colorectal Cancer

Phase 3 TBA

TBA

Trilaciclib

Breast Cancer ( I-SPY 2)

Phase 2 (Data)

Q4 2020

Rintodestrant (mono)

ER+, HER2- Breast Cancer

Phase 1/2a (Safety Data)

Q4 2020

Lerociclib (+ Tagrisso)

NSCLC

Phase 1/2

TBD

Lerociclib (+ fulvestrant)

ER+, HER2- Breast Cancer

Phase 1/2

TBD

Rintodestrant (+ palbociclib)

ER+/HER2- Breast Cancer

Phase 1a TBD

TBD

Recent Posts

See what the community is saying - click to see full post

GTHX - Announces Acceptance of NDA for Trilaciclib for Patients with Small Cell Lung Cancer

Trilaciclib NDA Filing (GTHX)

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon